A Phase 1/2, Randomized, Placebo-controlled, Double-blind, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of Single and Multiple Ascending Doses of AOC 1044 Administered Intravenously to Healthy Adult Volunteers and Participants With DMD Mutations Amenable to Exon 44 Skipping
Latest Information Update: 16 Aug 2024
At a glance
- Drugs AOC 1044 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Acronyms EXPLORE44
- Sponsors Avidity Biosciences
- 09 Aug 2024 Status changed from recruiting to active, no longer recruiting, according to an Avidity Biosciences media release.
- 09 Aug 2024 According to an Avidity Biosciences media release, company is hosting Volume 10 of its investor and analyst event series on August 9, 2024, beginning at 8:00 a.m. ET to discuss the initial data from the EXPLORE44TM trial of del-zota in people living with DMD44.
- 09 Aug 2024 Results presented in an Avidity Biosciences media release.